Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin
Public ClinicalTrials.gov record NCT00742859. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Parallel Group, Dose-Finding, Multicenter, Multinational Study of the Safety, Tolerability and Pilot Efficacy of Three Blinded Doses of the Oral Factor Xa Inhibitor Betrixaban Compared With Open-Label Dose-Adjusted Warfarin in Patients With Non-Valvular Atrial Fibrillation (EXPLORE Xa)
Study identification
- NCT ID
- NCT00742859
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Enrollment
- 508 participants
Conditions and interventions
Conditions
Interventions
- betrixaban Drug
- Warfarin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2008
- Primary completion
- Jul 31, 2009
- Completion
- Oct 31, 2009
- Last update posted
- Aug 6, 2023
2008 – 2009
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Portola Investigational Site | Anaheim | California | 92801 | — |
| Portola Investigational Site | Colorado Springs | Colorado | 80909 | — |
| Portola Investigational Site | Melbourne | Florida | 32901 | — |
| Portola Investigational Site | Miami | Florida | 33173 | — |
| Portola Investigational Site | Ormond Beach | Florida | 32174 | — |
| Portola Investigational Site | Pensacola | Florida | 32501 | — |
| Portola Investigational Site | Port Charlotte | Florida | 33952 | — |
| Portola Investigational Site | Aurora | Illinois | 60504 | — |
| Portola Investigational Site | Auburn | Maine | 04210 | — |
| Portola Investigational Site | Columbia | Maryland | 21044 | — |
| Portola Investigational Site | Salisbury | Maryland | 21804 | — |
| Portola Investigational Site | Towson | Maryland | 21204 | — |
| Portola Investigational Site | Tupelo | Mississippi | 38801 | — |
| Portola Investigational Site | St Louis | Missouri | 63110 | — |
| Portola Investigational Site | Poughkeepsie | New York | 12601 | — |
| Portola Investigational Site | Hillsboro | Oregon | 97123 | — |
| Portola Investigational Site | Wynnewood | Pennsylvania | 19096 | — |
| Portola Investigational Site | Rapid City | South Dakota | 57701 | — |
| Portola Investigational Site | Norfolk | Virginia | 23507 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00742859, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00742859 live on ClinicalTrials.gov.